Quanterix Corporation

Quanterix Corporation develops and sells ultrasensitive diagnostic instruments and assays, including its Simoa technology, which is used in biomedical research. The platform's core function of detecting biomarkers at extremely low concentrations is a tool employed in preclinical and clinical studies across the pharmaceutical and biotech industries. A significant portion of this research involves animal testing, as these studies are a standard, though exclusionary, step in therapeutic development and safety assessment. By manufacturing and selling equipment integral to this research pipeline, Quanterix's business model is materially linked to the commercial exploitation of animals in laboratory settings.

The company's technology is explicitly marketed to accelerate drug discovery and development, processes that rely heavily on animal data before human trials. For example, its instruments are used in neuroscience, oncology, and immunology research—fields where animal models are prevalent. While Quanterix does not conduct the tests itself, it produces the enabling tools for laboratories that do. This positions the company within the supply chain for animal testing, deriving revenue from the sale of equipment and consumables used in these experiments. No public commitment or company policy was found disavowing or seeking to reduce the use of its technology in animal-based research.